» Articles » PMID: 34858994

Molecular Characterization of the Clinical and Tumor Immune Microenvironment Signature of 5-methylcytosine-Related Regulators in Non-small Cell Lung Cancer

Overview
Specialty Cell Biology
Date 2021 Dec 3
PMID 34858994
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

DNA methylation is an important epigenetic modification, among which 5-methylcytosine methylation (5mC) is generally associated with tumorigenesis. Nonetheless, the potential roles of 5mC regulators in the tumor microenvironment (TME) remain unclear. The 5mC modification patterns of 1,374 lung adenocarcinoma samples were analyzed systematically. The correlation between the 5mC modification and tumor microenvironment cell infiltration was further assessed. The 5mCscore was developed to evaluate tumor mutation burden, immune check-point inhibitor response, and the clinical prognosis of individual tumors. Three 5mC modification patterns were established based on the clinical characteristics of 21 5mC regulators. According to the differential expression of 5mC regulators, three distinct 5mC gene cluster were also identified, which showed distinct TME immune cell infiltration patterns and clinical prognoses. The 5mCscore was constructed to evaluate the tumor mutation burden, immune check-point inhibitor response, and prognosis characteristics. We found that patients with a low 5mCscore had significant immune cell infiltration and increased clinical benefit. This study indicated that the 5mC modification is involved in regulating TME infiltration remodeling. Targeting 5mC modification regulators might be a novel strategy to treat lung cancer.

Citing Articles

Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures.

Omotesho Q, Escamilla A, Perez-Ruiz E, Frecha C, Rueda-Dominguez A, Barragan I Front Immunol. 2024; 15:1348156.

PMID: 38333212 PMC: 10851080. DOI: 10.3389/fimmu.2024.1348156.


Plasma Cell-Free Tumor Methylome as a Biomarker in Solid Tumors: Biology and Applications.

Sacdalan D, Haq S, Lok B Curr Oncol. 2024; 31(1):482-500.

PMID: 38248118 PMC: 10814449. DOI: 10.3390/curroncol31010033.


Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.

Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S Signal Transduct Target Ther. 2023; 8(1):210.

PMID: 37217462 PMC: 10203321. DOI: 10.1038/s41392-023-01480-x.


Molecular Characterization and Clinical Characteristics of m5C-Based RNA Methylation in Spinal Cord Injury: Validated by qPCR.

Cao L, Pi W, Zhang Q, Li Q Int J Genomics. 2022; 2022:5433860.

PMID: 36582430 PMC: 9794433. DOI: 10.1155/2022/5433860.


Comprehensive Analysis of 5-Methylcytosine (mC) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy.

Wang R, Guo Y, Ma P, Song Y, Min J, Zhao T Front Oncol. 2022; 12:851766.

PMID: 35433474 PMC: 9009261. DOI: 10.3389/fonc.2022.851766.


References
1.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

2.
Du J, Johnson L, Jacobsen S, Patel D . DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015; 16(9):519-32. PMC: 4672940. DOI: 10.1038/nrm4043. View

3.
Miyakuni K, Nishida J, Koinuma D, Nagae G, Aburatani H, Miyazono K . Genome-wide analysis of DNA methylation identifies the apoptosis-related gene UQCRH as a tumor suppressor in renal cancer. Mol Oncol. 2021; 16(3):732-749. PMC: 8807364. DOI: 10.1002/1878-0261.13040. View

4.
Zhao Q, Wang W, Li J, Yuan P, Liu Y, Li Y . The DNA cytosine-5-methyltransferase 3 (DNMT3) involved in regulation of CgIL-17 expression in the immune response of oyster Crassostrea gigas. Dev Comp Immunol. 2021; 123:104092. DOI: 10.1016/j.dci.2021.104092. View

5.
Wang H, Chen S, Meng D, Wu C, Zhu J, Jiang M . Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. Onco Targets Ther. 2021; 14:2953-2965. PMC: 8106479. DOI: 10.2147/OTT.S294993. View